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Purpose: To evaluate the patient satisfaction and health related quality of life (HRQoL) for 
levonorgestrel-releasing intrauterine system (LNG-IUS) versus conventional medical  treatments 
([CMTs] combined oral contraceptives, oral progestins, and antifibrinolytics, alone or in 
 combination) in Asian women with heavy menstrual bleeding (HMB).
Patients and methods: A total of 647 patients diagnosed with HMB were recruited to this 
non-interventional study from the eight participating countries in Asia. Patient satisfaction was 
recorded at the last visit (at 12 months or premature discontinuation). At each visit (at 3, 6, 
and 12 months), patients completed the menorrhagia multi-attribute scale (MMAS) to assess 
HRQoL.
Results: A total of 83.5% of patients on the LNG-IUS were “very satisfied” or at least “satisfied” 
with the therapeutic effect of HMB treatment, compared with 59.2% of patients with CMTs 
(P,0.05). The mean (± standard deviation) MMAS score increased from 41.4±24.5 to 87.7±21.4 
in the LNG-IUS arm, and from 44.1±24.9 to 73.1±25.3 in the CMTs arm. This increase was 
significantly higher in patients on the LNG-IUS, as compared with those on CMTs (P,0.05). 
The improvement in HRQoL in both treatment groups correlated with the body mass index of 
the patient, with larger improvement obtained in women with a higher body mass index.
Conclusion: The majority of women using the LNG-IUS or CMTs for HMB were satisfied with 
their treatment, and both treatment modalities were associated with significant improvements in 
HRQoL over time. The improvement was greater with the LNG-IUS, compared with CMTs.
Keywords: HRQoL, MMAS, menorrhagia, tranexamic acid, dysfunctional uterine bleeding
Introduction
Heavy menstrual bleeding (HMB) is defined as excessive menstrual blood loss, which 
may occur alone or in combination with other symptoms, and which has a negative 
impact on a woman’s physical, social, emotional, and/or material quality of life (QoL).1 
The perceived impact of bleeding on health-related quality of life (HRQoL) is one of 
the basic reasons why a patient with HMB seeks medical help, even if the menstrual 
blood loss is below the stipulated cut-off value of 80 mL per cycle.1–3 Hence, the pri-
mary aim in any treatment for HMB should be improved HRQoL.2 Yet most studies 
on treatment of HMB in the literature focus on the reduction of menstrual blood loss 
rather than HRQoL.4–11 In addition, many of the currently available HRQoL measures 
such as the Short Form 36 are not specific for HMB.12
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The levonorgestrel-releasing intrauterine system 
(LNG-IUS) has been shown to improve HRQoL to a similar 
extent to hysterectomy in a long-term randomized comparative 
study.13 Until recently, little data existed regarding the effect 
of commonly used therapies, such as oral contraceptives and 
tranexamic acid, on HRQoL of women suffering from HMB. 
Furthermore, these studies have generally been conducted in 
Europe or the US, and the data regarding Asian women’s expe-
rience of HMB is limited. In January 2013, the main results 
from the UK-based ECLIPSE trial (Effectiveness and cost-
effectiveness of Levonorgestrel containing Intrauterine system 
in Primary care against Standard treatment for Menorrhagia) 
were published.14 This randomized comparative study of the 
LNG-IUS versus usual treatment used the validated HMB-
specific QoL measure, the Menorrhagia Multi-Attribute Scale 
(MMAS),15 and showed that improvements in MMAS scores 
were significantly greater among women assigned to the LNG-
IUS than among those assigned to usual treatment. As this 
study was conducted in the UK, it is not known whether the 
results can be extrapolated to the Asia-Pacific population. The 
Mirena or conventional medical treatment (MiCo) for HMB 
study (conventional medical treatment [CMT], combined oral 
contraceptives, oral progestins and antifibrinolytics, alone 
or in combination), a large non-interventional study in the 
Asia-Pacific region, was initiated to address these knowledge 
gaps. The results regarding the continuation rate and treatment 
efficacy of the MiCo study have been reported earlier by our 
group.16 The present study reports the patient satisfaction and 
HRQoL data from the MiCo study using the HMB-specific 
MMAS QoL measure.
Material and methods
study design
This study design and methodology has been reported 
previously.16 In brief, this was a prospective observational 
cohort study with a non-interventional model. Informed 
consent was obtained from patients, and independent 
ethics committee or institutional review board approval was 
sought where necessary. The choice of treatment modality was 
not influenced by participation in the study and enrollment 
in the study did not warrant additional investigations. The 
study population was women between age 18 and 45 years 
who were not intending to become pregnant during the next 
year, with complaint of HMB over several consecutive cycles, 
without structural or histological abnormalities of the uterus, 
and who were eligible for pharmacological treatment. Patients 
who had contraindications and warnings regarding the study 
drugs; those on hormone therapy or with symptoms such as 
intermenstrual or postcoital bleeding (unless pathology was 
excluded via an endometrial biopsy); those with abdominally 
palpable fibroids, intracavitary fibroids, or a uterine length of 
more than 12 cm on ultrasound or hysteroscopy; and those 
on anticoagulants or other treatments known to cause menor-
rhagia (eg, copper intrauterine device) were excluded from 
the study. Investigators were asked to recruit consecutive 
patients from their routine clinical practice in the People’s 
Republic of China, Taiwan, Hong Kong, Indonesia, Malaysia, 
Pakistan, South Korea, and Thailand between September 2008 
and December 2010. The primary outcome measure was the 
cumulative continuation rate at 12 months stratified by the 
history of previous treatment(s) for HMB. The secondary 
outcome parameters were bleeding pattern, patient satisfaction 
at end of documentation, HRQoL, and safety profile. Subject 
satisfaction was recorded using a four-point Likert-like scale 
(very satisfied to dissatisfied) at the last visit (at 12 months 
or at premature discontinuation). In cases where the patient 
had received previous HMB treatment, the investigators were 
requested to compare the previous treatment and actual treat-
ment (LNG-IUS or CMTs), rating the experience as “much 
better,” “better,” “the same,” or “worse” based on retrospec-
tive recall.
evaluation of HrQol
At each visit, patients enrolled in the study were asked to 
complete the MMAS to assess the impact of therapy in terms 
of HRQoL.15 The MMAS questionnaire includes statements 
in six different domains; practical difficulties, impact on social 
life, psychological health, physical health, working life, and 
family life. Patients were asked to tick one statement in each 
of these domains. Each ticked statement corresponded to a 
score, and the addition of the six different scores provided 
the final MMAS score (0–100; 0= worst affected, 100= 
unaffected). It was mandatory to complete a questionnaire 
at both the initial visit and at least one follow-up visit, while 
it was voluntary on other visits. The mean MMAS score at 
baseline and the mean change over the course of the study 
was calculated. In addition, the results were stratified by 
treatment group, age group, body-mass-index (BMI) group, 
and country. The analyses used all available data. The mean 
change in MMAS score from baseline to the 12-month 
follow-up visit in both treatment groups (LNG-IUS or CMT) 
was evaluated using analysis of variance. Mean changes were 
also evaluated according to the BMI and age group.
Results
Patients
A total of 647 patients (LNG-IUS, n=483; CMTs, n=164) 
were recruited from the eight participating countries. 
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Three countries (Pakistan, South Korea, and the People’s 
Republic of China) contributed approximately 80% of the 
recruited patients. All patients were included in the safety 
analysis (full analysis set), while the per-protocol sample of 
572 patients (LNG-IUS, n=437; CMTs, n=135) were included 
in the efficacy analysis (Table 1). Because investigators 
recruited consecutive patients diagnosed with HMB to this 
non-interventional study, the number of subjects enrolled in 
each group could not be predetermined, thus resulting in an 
unequal size of the two treatment groups. The demographic 
and baseline characteristics, efficacy and safety results, as 
well as the study flow chart have been published previously.16 
In brief, the mean (± standard deviation) age of the patients 
was 37.8±4.9 years, their mean BMI was 23.5±4.6, and 58% 
had not received previous treatment for HMB, while 36.2% 
had received at least one treatment and data were missing 
for 5.8%. In the conventional HMB therapy group (n=135), 
75 patients (55.6%) received hormonal treatment, whereas 
33 (24.4%) and 25 (18.5%) patients were on antifibrinolytic 
treatment or a combination of both hormonal and antifibrin-
olytic treatment, respectively.
satisfaction with treatment
In the LNG-IUS group, over 80% of patients were “very 
 satisf ied” or “satisf ied” with their therapy for HMB, 
 compared with 59.2% of the patients using CMTs  (Figure 1). 
The difference between treatment groups was statistically 
significant (two-sided Fisher’s exact test for satisfaction at 
last visit documented: P,0.05; logrank test for time-to-
event: P,0.0001). In the CMTs group, there were no marked 
differences in the satisfaction rates within individual treat-
ments (hormonal versus antifibrinolytic versus combined).
Previous HMB treatment, that was applied for at least 
2 months, was recorded for 156/437 LNG-IUS patients 
(35.7%) and for 60/135 patients with CMTs (44.4%, not 
significant between treatment groups). Figure 2 displays the 
comparison of current therapy to previous therapy (women 
without previous therapy are included in the “missing” 
category). In the LNG-IUS group, more than one-third of 
the patients reported their current therapy as “much better” 
and more than 25% as “better” than previous therapy, while 
approximately 6% reported it to be “the same” and only 2% 
reported it as “worse”. In the CMTs group, ,10% of patients 
on CMTs rated their current treatment to be “much better” 
than previous therapy, and approximately 30% reported their 
current treatment to have “better” efficacy than their previ-
ous treatment (Figure 2). The difference between groups 
was statistically significant (P,0.05, post-hoc Wilcoxon 
rank sum test).
evaluation of HrQol
The majority of the patients (74.1% and 62.2% LNG-IUS 
and CMTs, respectively) completed the MMAS question-
naires at all four visits, while 15% of the overall population 
(14.9% and 15.6% LNG-IUS and CMTs, respectively) 
completed three questionnaires, 7.3% (5.9% and 11.9% 
LNG-IUS and CMTs, respectively) completed two 
 questionnaires, and 3.0% (2.1% and 5.9% LNG-IUS and 
CMTs, respectively) completed only one questionnaire. No 
questionnaires were returned by 3.1% (18/572) women: 12 
in the LNG-IUS and six in the CMTs group. The baseline 
mean (± standard deviation) MMAS score was 41.4±24.5 
in the LNG-IUS arm and 44.1±24.9 in the CMTs arm. 
In both treatment groups, the MMAS score significantly 
increased over the study period (P,0.05). At 12 months, 
the mean increase in the MMAS score from baseline to 
12 months was 51.1 in the LNG-IUS group and 29.9 in the 
CMTs group (Figure 3), and this difference was statistically 
significant (P,0.05).
The baseline scores of the patients in different BMI 
categories were fairly similar for both treatment groups, 
except that the score tended to be lower for patients with 
a BMI $30 kg/m2 compared with the other BMI groups 
(Figure 4). Both the treatment modality group (P,0.05) 
and the BMI group (P,0.05) had a significant effect on the 
change in the MMAS score from baseline to 12 months. 
The LNG-IUS was superior to CMTs and the greatest 
improvement was seen in those with a BMI $30 kg/m2 
(Figure 4). With regard to the different age groups and 
treatment modalities, there was a significant change in the 
MMAS score from baseline to 12 months (P,0.05). There 
was an overall difference in the level of the MMAS score for 
the different age groups, but age group had no significant 
Table 1 Patient disposition (per protocol population)
Country Total  
number of  
patients
LNG-IUS Conventional 
medical 
treatment
N % N % N %
People’s republic  
of china
154 26.9 130 29.7 24 17.8
Taiwan 26 4.5 17 3.9 9 6.7
Hong Kong 30 5.2 14 3.2 16 11.9
Indonesia 18 3.1 14 3.2 4 3.2
south Korea 187 32.7 154 35.2 33 24.4
Malaysia 15 2.6 9 2.1 6 4.4
Pakistan 109 19.1 76 17.4 33 24.4
Thailand 33 5.8 23 5.3 10 7.4
Total 572 100.0 437 100.0 135 100.0
Abbreviation: lng-IUs, levonorgestrel-releasing intrauterine system.
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effect on the change in the MMAS score from baseline to 
12 months (Figure 5).
Discussion
The present study describes real-life treatment patterns and 
satisfaction in a large group of women treated for HMB in the 
Asia-Pacific region. The results indicate that both the LNG-
IUS and CMTs improve the QoL of women suffering from 
HMB. Compared with women using CMTs, women using the 
LNG-IUS for HMB have a higher satisfaction rate and increase 
in QoL as measured by the MMAS scores. The results on the 
LNG-IUS are in line with Western data on HRQoL, reported by 
the SF36-questionnaire, with the LNG-IUS therapy in HMB.17 
The literature regarding QoL with CMTs is scarce, but the 
results from the ECLIPSE trial14 are in line with the results of 
the current study. Further stratification of the data based on the 
BMI shows that the heaviest women (BMI $30 kg/m2) derived 
the greatest benefit from both treatments. This is interesting, 
as obesity is considered to be a risk factor for HMB.
A systematic review published in 2002 on HRQoL instru-
ments for HMB concluded that there is a need to develop 
methodologically sound disease-specific QoL instruments 
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in HMB focusing both on face validity and measurement 
properties.18 Only two out of 19 studies used disease-specific 
QoL instruments, while the majority used the Short Form 
36 Health Survey Questionnaire (SF36).18 However, several 
questions on the SF36 questionnaire have been shown to be 
inappropriate or difficult to answer for women with HMB as 
symptoms are not generally constant, but cyclical. Therefore, 
the authors concluded that, if used on its own, the SF36 is 
inappropriate as a patient-based outcome measure in HMB. 
Our study used the disease-specific MMAS score, which has 
been used in other HMB trials.
A recent review on the cost-effectiveness and QoL of the 
LNG-IUS in treatment of HMB found 16 studies reporting 
on the QoL after treatment with the LNG-IUS for HMB.19 
Of note, none of these studies were performed in an Asian 
population. The authors concluded that, with a small number 
of exceptions, most HRQoL measurements improve with the 
LNG-IUS treatment, and that these improvements are, in most 
cases, at least similar to those achieved with hysterectomy 
or endometrial ablation.
The results in the current study on the improvement 
of HRQoL with LNG-IUS are in line with the published 
literature. The HRQoL data were available for the vast 
majority of subjects continuing treatment at any time point 
(see Results section); however, as the continuation rate was 
significantly lower with CMTs than with the LNG-IUS,16 
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the information was available for a lower proportion in 
the CMTs group. Although our study was not randomized, 
the results are remarkably similar compared with those 
recently reported in the ECLIPSE study.14 In the ECLIPSE 
study, greater improvements in MMAS were observed for 
the LNG-IUS from baseline to 6 months compared with 
usual treatment (P,0.001), and these improvements were 
maintained over a 2-year period (P,0.001). Improvements 
were noted across all the MMAS domains, including social 
life, family life, and work and daily routine. Importantly, 
after 2 years, more women continued using the LNS-IUS 
than their usual treatment (64 versus 38%; P,0.001).14 
While the baseline MMAS scores were similar to those in 
our study (around 40 points), the magnitude of increase was 
somewhat lower in the ECLIPSE study, and the scores at 
12 months were approximately 80 and 60 in the LNG-IUS 
group and the usual treatment groups, compared with 92.5 
and 74 in the present study, respectively. This would indicate 
that the improvement of QoL achieved by treatment for HMB 
may be even greater in Asia-Pacific populations compared 
with the UK female population.
Obese women (BMI $30 kg/m2) tended to have a lower 
baseline QoL than women with a normal BMI or overweight 
women (BMI 25–29 kg/m2), both in our study and in the 
ECLIPSE study.14 In both studies, the greatest improvements 
in MMAS scores were obtained in obese women using the 
LNG-IUS.
In a prospective study of 56 morbidly obese women, 
the LNG-IUS was found to be an effective treatment in 
75% of women.20 In our study, the HRQoL of obese women 
improved to an equal level to that of normal and overweight 
women after 12 months of follow-up with the LNG-IUS. 
Although, in women treated with CMTs, the improvement 
in the HRQoL score after 12 months also correlated with 
the BMI, it remained lower in the obese group as compared 
to the normal weight group. These results suggest that treat-
ment with the LNG-IUS results in an equally high HRQoL 
status, regardless of BMI. In contrast, the final HRQoL may 
not be optimal in overweight and obese women treated with 
CMTs. This could be explained by the fact that the endome-
trial effects of the LNG-IUS are equally strong regardless of 
BMI, while the treatment effect may be less in overweight 
and obese women treated with CMTs as compared to lean 
and normal-weight women due to the higher distribution 
volume of the latter group. It can also be speculated that 
higher doses of CMTs (where feasible) should be used for 
overweight/obese women.
The major limitations of this study relate to its setting 
as an observational cohort study. Due to the nature of this 
setting, the two treatment cohorts can never be completely 
identical; however, with regard to the baseline characteristics, 
the two cohorts were very similar in this study.  Nevertheless, 
our results were remarkably similar to those observed in 
the UK-based randomized ECLIPSE study; we  therefore 
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consider the results of our study representative of the 
improvement of HRQoL in Asia-Pacific women. The treat-
ment satisfaction was recorded by the treating physician to 
the study documents; therefore, a “courtesy bias” is possible. 
Another limitation is that the MMAS questionnaire was not 
fully linguistically validated. However, the vast majority of 
women who continued treatment at any time point filled out 
the questionnaire, indicating that they did not have major 
problems in understanding the questionnaire. In addition, to 
the best knowledge of the authors, no local norm data exist for 
the participating countries for HRQoL by MMAS, therefore 
preventing any comparisons with previous data.
Conclusion
In conclusion, these study results indicate that HMB has 
significant negative impact on HRQoL in women from 
the Asia-Pacific region, echoing the experience from the 
 European and North American studies. Patient satisfaction 
data in this study indicate that a significant proportion of 
women in the Asia-Pacific region do not attain optimal sat-
isfaction with CMTs for HMB, and the LNG-IUS may offer 
considerable improvement in the overall treatment outcomes 
in these patients. While HRQoL improved in women treated 
both with CMTs and the LNG-IUS, the level of HRQoL 
that was reached with the LNG-IUS was higher compared 
to that reached with CMTs. After 12 months of follow-up, 
the HRQoL that was reached with the LNG-IUS was similar 
in women in all BMI categories, whereas the HRQoL that 
was reached with CMTs was lower in overweight and obese 
women, compared to normal-weight and lean women.
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